BlackRock Amends Anika Therapeutics Stake as of Dec 31, 2023
Ticker: ANIK · Form: SC 13G/A · Filed: Jan 24, 2024 · CIK: 898437
| Field | Detail |
|---|---|
| Company | Anika Therapeutics, Inc. (ANIK) |
| Form Type | SC 13G/A |
| Filed Date | Jan 24, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, form-13G, investor-activity
TL;DR
**BlackRock updated its Anika Therapeutics stake, watch for potential market reaction.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 24, 2024, indicating a change in its ownership of Anika Therapeutics, Inc. common stock as of December 31, 2023. While the exact percentage of ownership isn't detailed in the provided text, this amendment signals that BlackRock, a major institutional investor, has adjusted its stake. This matters to investors because large institutional movements can influence stock price and reflect a significant investor's updated view on the company's prospects.
Why It Matters
This filing shows that a major institutional investor, BlackRock, has changed its position in Anika Therapeutics, which can signal shifts in market sentiment or investment strategy for the company.
Risk Assessment
Risk Level: low — This is a routine amendment filing by a large institutional investor, indicating a change in ownership rather than a new, high-impact event.
Analyst Insight
Investors should monitor Anika Therapeutics' stock performance and look for further details on BlackRock's specific changes in ownership (e.g., increase or decrease) in subsequent filings or news to understand the full implications.
Key Numbers
- 005-45573 — SEC File Number (identifies Anika Therapeutics, Inc.'s registration with the SEC)
- 035255108 — CUSIP Number (unique identifier for Anika Therapeutics, Inc. Common Stock)
- 3 — Amendment Number (indicates this is the third amendment to BlackRock's Schedule 13G filing for Anika Therapeutics)
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A amendment
- Anika Therapeutics, Inc. (company) — the subject company whose common stock is being reported on
- December 31, 2023 (date) — the date of the event which required the filing of this statement
- January 24, 2024 (date) — the date the SC 13G/A was filed
- 0000898437 (number) — Central Index Key (CIK) for Anika Therapeutics, Inc.
Forward-Looking Statements
- BlackRock's updated stake could lead to short-term price volatility for Anika Therapeutics. (Anika Therapeutics, Inc.) — medium confidence, target: Q1 2024
- Other institutional investors may review their positions in Anika Therapeutics following BlackRock's amendment. (institutional investors) — medium confidence, target: Q1 2024
FAQ
What type of filing is this and who filed it?
This is an SC 13G/A (Amendment No: 3) filing, which was filed by BlackRock Inc. regarding its ownership in Anika Therapeutics, Inc.
What is the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' is December 31, 2023, as stated in the filing.
What is the CUSIP number for the securities mentioned in this filing?
The CUSIP number for the Common Stock of Anika Therapeutics, Inc. is 035255108, according to the filing.
What is the business address of Anika Therapeutics, Inc.?
Anika Therapeutics, Inc.'s business address is 32 Wiggins Avenue, Bedford, MA 01730, with a business phone of (781) 457-9000.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), as indicated by the checked box in the filing.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 24, 2024 regarding Anika Therapeutics, Inc. (ANIK).